Botulinumtoxin A

Zusammenfassung

Botulinumtoxin A (Bont A) wird in der Nervenheilkunde gezielt zur Behandlung spezifischer Bewegungsstörungen wie Torticollis spasmodicus und Blepharospasmus eingesetzt. Jenseits der medizinischen Indikationen hat sich Bont A zu einem der bekanntesten LifestyleMedikamente für die Faltenbehandlung etabliert. Diese Übersicht stellt diese Entwicklung anhand evidenzbasierter Studiendaten aus der ästhetischen Medizin vor. Dabei werden die auf dem Markt befindlichen pharmazeutischen Präparate Botox®, Dysport® und Xeomin® sowie deren Lifestyle-Pendants (Vistabel®, Azzalure® und Bocouture®) berücksichtigt. Darüber hinaus wird die Behandlung der primären fokalen Hyperhidrose als medizinisch abzugrenzende Entität in Hinblick auf die Lebensqualität der Betroffenen dargestellt.

Summary

Botulinum toxin A (Bont A) has become the mainstay of therapy for certain neurologic disorders such as torticollis spasmodicus and blepharospasm. Beyond its pure medical uses, Bont A has emerged as one of the most popular life-style products to treat facial wrinkles. This review addresses Bont A uses within the field of aesthetic procedures established by the standards of evidence-based medicine. Presently, three Bont A products are approved in most European countries which are Botox®, Dysport® und Xeomin® for medical uses and their corresponding life-style products Vistabel®, Azzalure® and Bocouture®. Apart from aesthetic indications, patients with severe primary focal hyperhidrosis suffer from a medical condition that is readily treatable by intradermal Bont A injections resulting in effective disease control and significant improvement of quality of life which must not be confused with life-style.

Schlüsselwörter

Botulinumtoxin A - Lebensqualität - ästhetische Medizin - Hyperhidrose - Injektionen - Lifestyle - evidenzbasierte Medizin

Keywords

Botulinum toxin A - quality of life - aesthetic medicine - hyperhidrosis - injections - life-style - evidence-based medicine

• Literatur

• 1 Ceballos-Baumann A. [Botulinum toxin. Development for therapeutic purposes]. Nervenarzt 2008; 79 (Suppl. 01) 3-8.
• 2 Carruthers A, Carruthers J. History of the cosmetic use of Botulinum A exotoxin. Dermatol Surg 1998; 24 (11) 1168-70.
• 3 Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin Cutan Med Surg 2001; 20 (02) 71-84.
• 4 Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18: 17-21.
• 5 Carruthers A. Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles. New York: Marcel Dekker 1994
• 6 Lowe NJ, Maxwell A, Harper H. Botulinum-A exotoxin for glabellar folds: a double blind, placebo controlled study with an electromyographic injection technique. J Am Acad Dermatol 1996; 35: 569-72.
• 7 Carruthers JA. et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46 (06) 840-9.
• 8 Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29 (08) 802-9.
• 9 Blitzer A. et al. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997; 123 (04) 389-92.
• 10 Carruthers J, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg 2004; 114 (Suppl. 06) 1S-22S.
• 11 Ascher B. et al. A multicenter, randomized, doubleblind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51 (02) 223-33.
• 12 Rzany B. et al. Efficacy and safety of 3and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142 (03) 320-6.
• 13 Rzany B. et al. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 2007; 33 (1 Spec No.): S18-25.
• 14 Monheit GD, Cohen JL. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol 2009; 61 (03) 421-5.
• 15 Borodic G. Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. Ophthal Plast Reconstr Surg 2006; 22 (03) 239-40.
• 16 Lee SK. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg 2007; 33 (1 Spec No.): S105-10.
• 17 Heckmann H. et al. (eds.). Botulinumtoxin in der Dermatologie (2. Auf.). München: Urban & Vogel 2006
• 18 Lowe NJ. et al. Double-blind, randomized, placebocontrolled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet. Dermatol Surg 2005; 31 (03) 257-62.
• 19 Gassia V, Beylot C, Bechaux S, Michaud T. [Botulinum toxin injection techniques in the lower third and middle of the face, the neck and the decollete: the “Nefertiti lift”]. Ann Dermatol Venereol 2009; 136 (Suppl. 04) S111-8.
• 20 Carruthers J, Carruthers A. Botulinum toxin in facial rejuvenation: an update. Dermatol Clin 2009; 27 (04) 417-25.
• 21 Wohlfarth K. et al. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997; 355 (03) 335-40.
• 22 Dressler D, Rothwell JC, Marsden CD. Comparing biological potencies of Botox and Dysport with a mouse diaphragm model may mislead [letter]. J Neurol. 1998 245. (6–7).
• 23 Lowe NJ. Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Dermatol Surg 1998; 24 (11) 1216-8.
• 24 Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006; 13 (Suppl. 01) 2-10.
• 25 Frevert J. Xeomin: an innovative new botulinum toxin type A. Eur J Neurol 2009; 16 (Suppl. 02) 11-3.
• 26 Trindade ARde Almeida, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec No.): S37-43.
• 27 Stotland MA, Kowalski JW, Ray BB. Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study. Plast Reconstr Surg 2007; 120 (05) 1386-94.
• 28 Carruthers A, Carruthers J. A single-center dosecomparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients’ perception of treatment outcomes. J Drugs Dermatol 2009; 08 (10) 924-9.
• 29 Lewis MB, Bowler PJ. Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol 2009; 08 (01) 24-6.
• 30 Dayan SH. et al. Botulinum toxin a can positively impact first impression. Dermatol Surg 2008; 34 (Suppl. 01) S40-7.
• 31 Heckmann M. et al. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness,and fear. J Am Acad Dermatol 2003; 49 (02) 213-6.
• 32 Hennenlotter A. et al. The link between facial feedback and neural activity within central circuitries of emotion-new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex 2009; 19 (03) 537-42.
• 33 Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg 2006; 32 (05) 645-9.
• 34 Heckmann M, Ceballos-Baumann A. Botulinum toxin overrides depression: not surprising, yet sensational. Dermatol Surg 2007; 33 (06) 765.
• 35 Heckmann M, Plewig G. Behandlung der Hyperhidrose mit Botulinumtoxin-A. Dt Ärztebl 2000; 97: A2850-51.
• 36 Worle B, Rapprich S, Heckmann M. Definition and treatment of primary hyperhidrosis. J Dtsch Dermatol Ges 2007; 05 (07) 625-8.
• 37 Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. II. Disorders of sweat gland function. J Am Acad Dermatol 1989; 20: 713-26.
• 38 Heckmann M. et al. Botulinum beyond wrinkles. Dermatol Surgery 1997; 23: 1221-2.
• 39 Hamm H. et al. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology 2006; 212 (04) 343-53.
• 40 Naumann MK, Hamm H, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002; 147 (06) 1218-26.
• 41 Weber A. et al. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. Br J Dermatol 2005; 152 (02) 342-5.
• 42 Heckmann M, Schaller M, Breit S, Plewig G. Evaluation of therapeutic success of hyperhidrosis therapy. Arch Dermatol 2001; 137: 94.
• 43 Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001; 344 (07) 488-93.
• 44 Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. Bmj 2001; 323 (7313): 596.
• 45 Hornberger J. et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 2004; 51 (02) 274-86.
• 46 Heckmann M. Diagnosis and treatment of focal primary hyperhidrosis: Part I. Contemporary Dermatology 2004; 01 (11) 1-6.
• 47 Drobik C, Laskawi R, Schwab S. Therapie des FreySyndroms mit Botulinum toxin A. Erfahrungen mit einer neuen Behandlungsmethode. HNO 1995; 43 (11) 644-8.